구강회복응용과학지 (Journal of Dental Rehabilitation and Applied Science)

  • 제26권1호
  • /
  • Pages.69-75
  • /
  • 2010
  • /
  • 2384-4353(pISSN)
  • /
  • 2384-4272(eISSN)
대한턱관절교합학회 (Korean Academy of Stomatognathic Function and Occlusion)
권호 표지

덴탈 프리스케일로 평가한 보툴리눔 A형 독소 반복 주사 후 근육의 약화

Muscle Weakness after Repeated Injection of Botulinum Toxin Type A Evaluated by Dental Prescale

  • 변영섭 (연세대학교 치과대학 구강내과학교실) ;
  • 송지희 (연세대학교 치과대학 구강내과학교실) ;
  • 최영찬 (연세대학교 치과대학 구강내과학교실) ;
  • 김성택 (연세대학교 치과대학 구강내과학교실)
  • Byun, Young-Sub (Department of Oral medicine, college of dentistry, Yonsei University) ;
  • Song, Ji-Hee (Department of Oral medicine, college of dentistry, Yonsei University) ;
  • Choi, Young-Chan (Department of Oral medicine, college of dentistry, Yonsei University) ;
  • Kim, Seong-Taek (Department of Oral medicine, college of dentistry, Yonsei University)
  • 투고 : 2010.02.05
  • 심사 : 2010.03.25
  • 발행 : 2010.03.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A형 보툴리눔 독소(botulinum toxin type A, BTX-A)는 교근 비대의 치료에 성공적으로 적용되어 왔지만 주사 부위 근육의 약화를 초래한다. 이 연구는 BTX-A를 사람 교근에 주사한 후 최대 교합력(Maximum Bite Force, MBF) 의 변화를 측정하고, 반복 주사의 효과를 평가하기 위해 시행되었다. 30명의 자원자들을 18주간 추적 관찰하고, 최대 교합력을 측정하였다. 1차 주사로부터 18주가 경과한 후 시술에 만족한 16명은 제외하고 나머지 14명에게 반복 주사를 시행하였고, 다시 18주간 측정하였다. 평균 최대 교합력은 주사 2주 후 20% 감소하였다가 4주부터 점차 회복되었으며, 12주 뒤에는 주사 이전 수준으로 회복되었다. 최대 교합력은 주사 전과 주사 2주, 4주, 8주 후에서 유의한 차이를 보였다(p<.05). 반복 주사군(n=14)의 최대 교합력은 6주에 두드러진 감소를 보였다가(p<.05) 12주간 점차 회복되었다. 실험군이 경험한 불편감의 수준은 일반적인 저작에는 거의 영향을 미치지 않았다.

Botulinum toxin type A(BTX-A) has been applied successfully to treat masseteric hypertrophy. However it can cause muscle weakness. This study was designed to measure the change in maximum bite force(MBF) after BTX-A injection into human masseter muscle and to evaluate the influence of a booster(repeated) injection. Thirty volunteers completed 18-week follow-up and MBF was measured. At 18 weeks after the first injection, a booster injection was given to 14 patients and they were followed up until 18 weeks from the booster injection. The mean MBF was approximately 20% lower at 2 weeks than before the injection, and it recovered gradually after 4 weeks to return to the preinjection level at 12 weeks. The MBF differed significantly between before the injection and at 2, 4, and 8 weeks after the injection(p<0.05). In booster injection group(n=14),the MBF decreased markedly at 6 weeks(p<0.05),and it recovered gradually in 12 weeks. The MBF was significantly reduced after booster injection of BTX-A into the human masseter muscle. The degree of discomfort experienced by the subjects had little effect on normal mastication.

키워드

참고문헌

  1. Jankovic, J., Brin, M. F. Therapeutic uses of botulinum toxin. NEnglJMed 1991;324:1186-1194. https://doi.org/10.1056/NEJM199104253241707
  2. Simpson, L. L. Botulinum toxin: a deadly poison sheds its negative image. AnnInternMed 1996;125:616-617. https://doi.org/10.7326/0003-4819-125-7-199610010-00013
  3. Carruthers, J. D., Carruthers, J. A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. JDermatolSurgOncol 1992;18:17-21. https://doi.org/10.1111/j.1524-4725.1992.tb03295.x
  4. Blitzer, A., Brin, M. F., Keen, M. S., et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. ArchOtolaryngolHeadNeckSurg 1993;119:1018-1022. https://doi.org/10.1001/archotol.1993.01880210108015
  5. Carruthers, J. A., Lowe, N. J., Menter, M. A., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. JAmAcadDermatol 2002;46:840-849. https://doi.org/10.1067/mjd.2002.121356
  6. Blitzer, A., Binder, W. J., Aviv, J. E., et al. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. ArchOtolaryngolHeadNeckSurg 1997;123:389-392. https://doi.org/10.1001/archoto.123.4.389
  7. Clark, G. T. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. PhysMedRehabilClinNAm 2003;14:727-748. https://doi.org/10.1016/S1047-9651(03)00044-5
  8. Moore, A. P., Wood, G. D. The medical management of masseteric hypertrophy with botulinum toxin type A. BrJOralMaxillofacSurg 1994;32:26-28. https://doi.org/10.1016/0266-4356(94)90168-6
  9. To, E. W., Ahuja, A. T., Ho, W. S., et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. BrJPlastSurg 2001;54:197-200.
  10. Choe, S. W., Cho, W. I., Lee, C. K., et al. Effects of botulinum toxin type A on contouring of the lower face. 2005;31:502-507;discussion507. https://doi.org/10.1097/00042728-200505000-00002
  11. Kim, N. H., Chung, J. H., Park, R. H., et al. The use of botulinum toxin type A in aesthetic mandibular contouring. PlastReconstrSurg 2005;115:919-930. https://doi.org/10.1097/01.PRS.0000153236.79775.A0
  12. Kim, H. J., Yum, K. W., Lee, S. S., et al. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. 2003;29:484-489. https://doi.org/10.1046/j.1524-4725.2003.29117.x
  13. Park, M. Y., Ahn, K. Y., Jung, D. S. Botulinum toxin type A treatment for contouring of the lower face. 2003;29:477-483. https://doi.org/10.1046/j.1524-4725.2003.29116.x
  14. Kim, J. H., Shin, J. H., Kim, S. T., et al. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurementsted tuman masseter muscle. PlastReconstrSurg 2007;119:711-717. https://doi.org/10.1097/01.prs.0000239453.67423.99
  15. Yu, C. C., Chen, P. K., Chen, Y. R. Botulinum toxin a for lower facial contouring: a prospective study. AestheticPlastSurg 2007;31:445-451;discussion452. https://doi.org/10.1007/s00266-007-0081-8
  16. Alam, M., Dover, J. S., Klein, A. W., et al. Botulinum a exotoxin for hyperfunctional facial lines: where not to inject. ArchDermatol 2002;138:1180-1185. https://doi.org/10.1001/archderm.138.9.1180
  17. Ahn, K. Y., Kim, S. T. The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy. PlastReconstrSurg 2007;120:1662-1666. https://doi.org/10.1097/01.prs.0000282309.94147.22
  18. Borodic, G. E., Ferrante, R., Pearce, L. B., et al. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. MovDisord 9:31-39,1994. https://doi.org/10.1002/mds.870090106
  19. Borodic, G. E., Ferrante, R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. JClinNeuroophthalmol 1992;12:121-127. https://doi.org/10.3109/01658109209058127
  20. Rzany B,Dill-Muller D,Grablowitz D,Heckmann M,Caird D;German-Austrian Retrospective Study Group. Repeated botulinumtoxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. 2007;33:S18-25. https://doi.org/10.1111/j.1524-4725.2006.32327.x
  21. Oshima, M., Middlebrook, J. L., Atassi, M. Z. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. ImmunolLett 1998;60:7-12. https://doi.org/10.1016/S0165-2478(97)00124-7